Cargando…

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

BACKGROUND: Higher infliximab trough levels (TLs) correlate with better clinical, inflammatory, and endoscopic outcomes among inflammatory bowel disease (IBD) patients. Although standard scheduled infliximab therapy regimen consists of infusions at pre-defined time-points (weeks 0, 2, 6, and every 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ben-Shatach, Zohar, Ziv-Baran, Tomer, Fudim, Ella, Yavzori, Miri, Picard, Orit, Levartovsky, Asaf, Selinger, Limor, Weiss, Batia, Kopylov, Uri, Eliakim, Rami, Ungar, Bella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133860/ https://www.ncbi.nlm.nih.gov/pubmed/35646158 http://dx.doi.org/10.1177/17562848221083395

Ejemplares similares

Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
por: Levartovsky, Asaf, et al.
Publicado: (2023)

Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
por: Ungar, Bella, et al.
Publicado: (2015)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis
por: Yablecovitch, Doron, et al.
Publicado: (2019)

Signs and Symptoms of Acute Bowel Inflammation and the Risk of Progression to Inflammatory Bowel Disease: A Retrospective Analysis
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists
por: Vaisman-Mentesh, Anna, et al.
Publicado: (2019)

Distal Fecal Wash Host Transcriptomics Identifies Inflammation Throughout the Colon and Terminal Ileum
por: Dan, Stav, et al.
Publicado: (2023)

Immune function in newborns with in-utero exposure to anti-TNFα therapy
por: Weiss, Batia, et al.
Publicado: (2022)

Comprehensive Management of Inflammatory Bowel Disease: What’s Next
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Thromboprophylaxis for Hospitalized Patients with Inflammatory Bowel Disease—Are We There Yet?
por: Levartovsky, Asaf, et al.
Publicado: (2020)

Middle small-bowel segment Lewis score may predict long-term outcomes among patients with quiescent Crohn’s disease
por: Ukashi, Offir, et al.
Publicado: (2023)

Video Capsule Endoscopy Plays an Important Role in the Management of Crohn’s Disease
por: Levartovsky, Asaf, et al.
Publicado: (2023)

Serum Syndecan-1: A Novel Biomarker for Pancreatic Ductal Adenocarcinoma
por: Yablecovitch, Doron, et al.
Publicado: (2022)

Characterization of blood-derived exosomal hTERT mRNA as a biomarker for colon cancer and Lynch syndrome
por: Laish, Ido, et al.
Publicado: (2022)

Machine learning for prediction of intra-abdominal abscesses in patients with Crohn’s disease visiting the emergency department
por: Levartovsky, Asaf, et al.
Publicado: (2021)

Prediction of Recurrent Emergency Department Visits among Patients with Crohn’s Disease: A Retrospective Study
por: Mahajna, Hussein, et al.
Publicado: (2020)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Incidentally Diagnosed Asymptomatic Crohn’s Disease: A Retrospective Cohort Study of Long-Term Clinical Outcomes
por: Grinman, Ana, et al.
Publicado: (2022)

Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn’s Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab
por: Sorrentino, Dario, et al.
Publicado: (2015)

Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
por: Kwon, Yiyoung, et al.
Publicado: (2022)

Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy
por: Huang, Vivian W., et al.
Publicado: (2015)

Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease
por: Lahat, Adi, et al.
Publicado: (2017)

Treatment of acute severe ulcerative colitis using accelerated infliximab regimen based on infliximab trough level: A case report
por: Garate, Ana Lorena Sousa de Vasconcelos, et al.
Publicado: (2021)

Infliximab trough level combined with inflammatory biomarkers predict long-term endoscopic outcomes in Crohn’s disease under infliximab therapy
por: Cao, Wan-Ting, et al.
Publicado: (2022)

Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease
por: Choi, So Yoon, et al.
Publicado: (2023)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
por: van der Maas, Aatke, et al.
Publicado: (2012)

Advances in the development of new biologics in inflammatory bowel disease
por: Ungar, Bella, et al.
Publicado: (2016)

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease
por: Sekhri, Shaina, et al.
Publicado: (2021)

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease
por: Orts, Beatriz, et al.
Publicado: (2022)

Calprotectin and the Magnitude of Antibodies to Infliximab in Clinically-stable Ulcerative Colitis Patients are More Relevant Than Infliximab Trough Levels and Pharmacokinetics for Therapeutic Escalation
por: Magro, Fernando, et al.
Publicado: (2017)

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn’s Disease Comparing, between CT-P13 and Originator Infliximab
por: Park, Jihye, et al.
Publicado: (2023)

Effect of Weakly Interacting Cosolutes on Lysozyme Conformations
por: Levartovsky, Yehonatan, et al.
Publicado: (2018)

Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2017)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
por: Koga, Akihiro, et al.
Publicado: (2018)

Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2019)

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
por: Theodoraki, Eirini, et al.
Publicado: (2021)

Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
por: Gu, Bonita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2b0h85jskeb65a9aa9bebo2d4c